Interesting exploratory ctDNA data from EV-304/KEYNOTE-B15 at #ESMO26 in cisplatin-eligible MIBC.
🔹 ctDNA clearance: 82.1% with EV+P vs 66.7% with gem/cis
🔹 Baseline ctDNA+ patients derived substantial EFS benefit from EV+P (HR 0.54)
🔹 Persistent ctDNA positivity after surgery was associated with poor outcomes regardless of treatment.
ctDNA is a powerful prognostic biomarker, but can it guide treatment selection or bladder preservation? More work is needed.
#BladderCancer #ctDNA
436 views · 8 likes · 5 reposts · 0 replies
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.org- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.orgSource: David H Aggen, MD PhD · x.com